Happy New Year from OncoAlert @aftimosp.bsky.social @coffeemommy.bsky.social @drjnaidoo.bsky.social @agerikssonmd.bsky.social @jackwestmd.bsky.social @raalbany.bsky.social @drbonillaonc.bsky.social @stephenvliu.bsky.social @darcyburbage.bsky.social @itsnotpink.bsky.social

OncoAlert and partners (ESSO, ESGO, MASCC & SIOG) Proudly Announce 2/3 of our faculty, more soon Register HERE buff.ly/3CChgre @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @erikahamilton9.bsky.social @agerikssonmd.bsky.social @drjnaidoo.bsky.social

OA RoundUp🚨Nov 15-21 youtu.be/BDg6UDh2WvE @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @agerikssonmd.bsky.social @fernandoonco.bsky.social @icromeattini.bsky.social @drnataliagandur.bsky.social @biagioricciutimd.bsky.social @yukselurun.bsky.social

The OncoAlert Round Up November 15-21, 2024

YouTube video by OncoAlert 360

youtu.be

Looking forward to the upcoming 2024 #OncoAlertColloquium #MedEd #Oncology #GynOncology

The OncoAlert Network 🚨@oncoalert.bsky.social · 2y ago

OncoAlert along with our partners at ESSO, ESGO, MASCC & SIOG Proudly Announce 1/3 of our faculty, more soon@ Register HERE https://buff.ly/3CChgre @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @erikahamilton9.bsky.social @agerikssonmd.bsky.social

CHIPOR Out on The Lancet Oncology explored HIPEC w/cytoreductive surgery for recurrent ovarian cancer After 1st relapse post-platinum tx, pts were randomized to surgery with/without HIPEC. HIPEC increased median survival from 45.8 to 54.3 months but caused more SAEs https://buff.ly/3ZjXnOF